Bioprocessing of Mesenchymal Stem Cells and Their Derivatives: Toward Cell-Free Therapeutics

Simple item page
dc.contributor.authorPhelps, Jolene
dc.contributor.authorSanati-Nezhad, Amir
dc.contributor.authorUngrin, Mark
dc.contributor.authorDuncan, Neil A.
dc.contributor.authorSen, Arindom
dc.date.accessioned2018-09-26T07:28:12Z
dc.date.available2018-09-26T07:28:12Z
dc.date.issued2018-09-12
dc.date.updated2018-09-26T07:28:12Z
dc.description.abstractMesenchymal stem cells (MSCs) have attracted tremendous research interest due to their ability to repair tissues and reduce inflammation when implanted into a damaged or diseased site. These therapeutic effects have been largely attributed to the collection of biomolecules they secrete (i.e., their secretome). Recent studies have provided evidence that similar effects may be produced by utilizing only the secretome fraction containing extracellular vesicles (EVs). EVs are cell-derived, membrane-bound vesicles that contain various biomolecules. Due to their small size and relative mobility, they provide a stable mechanism to deliver biomolecules (i.e., biological signals) throughout an organism. The use of the MSC secretome, or its components, has advantages over the implantation of the MSCs themselves: (i) signals can be bioengineered and scaled to specific dosages, and (ii) the nonliving nature of the secretome enables it to be efficiently stored and transported. However, since the composition and therapeutic benefit of the secretome can be influenced by cell source, culture conditions, isolation methods, and storage conditions, there is a need for standardization of bioprocessing parameters. This review focuses on key parameters within the MSC culture environment that affect the nature and functionality of the secretome. This information is pertinent to the development of bioprocesses aimed at scaling up the production of secretome-derived products for their use as therapeutics.
dc.description.versionPeer Reviewed
dc.identifier.citationJolene Phelps, Amir Sanati-Nezhad, Mark Ungrin, Neil A. Duncan, and Arindom Sen, “Bioprocessing of Mesenchymal Stem Cells and Their Derivatives: Toward Cell-Free Therapeutics,” Stem Cells International, vol. 2018, Article ID 9415367, 23 pages, 2018. doi:10.1155/2018/9415367
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/32981
dc.identifier.urihttp://dx.doi.org/10.1155/2018/9415367
dc.identifier.urihttp://hdl.handle.net/1880/107818
dc.language.rfc3066en
dc.rights.holderCopyright © 2018 Jolene Phelps et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.titleBioprocessing of Mesenchymal Stem Cells and Their Derivatives: Toward Cell-Free Therapeutics
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
SCI.2018.9415367.pdf
Size:
2.2 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications